After an impressive Q3, what's next for Stryker?

Eric Oliver -   Print  |
  • Small
  • Medium
  • Large

Stryker beat industry analysts and reported $1.39 earnings per share in the third quarter, a 11.2 percent year-over-year improvement , but what's next for the orthopedic device maker?

Here are four things Market Realist thinks you should know.

1. Analyst ratings vary over Stryker. Of 26 brokerage companies, 16 labeled Stryker a "buy," eight labeled it a "hold" and two labeled it a "sell."

2. The 12-month outlook for Stryker estimates it'll trade at $127.10 this time next year. As of Nov. 17, 2016, Stryker was trading at $110.70.

3. The company believes President-elect Donald Trump (R) will benefit the medical device industry, predicting that Mr. Trump will repeal the current 2.3 percent medical device tax. The company also stated that the future of the ACA will have little impact on its business.

4. Stryker has aligned itself with four core strategies going forward: business unit specialization, acquisitions, international growth and cost transformation.

More articles on orthopedic and spinal devices:
Zimmer Biomet uveils Vault Reconstruction System: 3 quick points
EIT receives investment for international growth, 3-D-printing product development: 5 points
Medtronic, Xtant Medical, Titan Spine & more: 13 key note

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

Featured Webinars

Featured Whitepapers

Featured Podcast